Effect of roflumilast in patients with severe COPD and a history of hospitalisation Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017 Year: 2017
Effects of roflumilast in highly symptomatic COPD patients Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care Year: 2012
Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013
The effect of formoterol in elderly COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005
The direct costs of exacerbations in COPD and the effect of cilomilast treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Efficacy of roflumilast in the frequent exacerbation COPD phenotype Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials Source: Eur Respir J 2006; 28: Suppl. 50, 175s Year: 2006
Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD Source: Annual Congress 2011 - COPD management Year: 2011
The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients Source: Eur Respir J 2014; 44: 527-529 Year: 2014
Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Risk factors for discontinuation of roflumilast in COPD patients Source: International Congress 2017 – COPD management Year: 2017
Salmeterol 50μg bid significantly reduces moderate-severe exacerbations in patients with all severities of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 68s Year: 2003
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007
Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 512s Year: 2004